Univariate, bivariate and multivariate analyses of baseline MBDA score, DAS28 and CRP as predictors of 1-year radiographic progression
| OR* | 95% CI | p Value† | |
|---|---|---|---|
| Univariate analyses | |||
| Baseline MBDA score | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline DAS28-ESR | 1.31 | (0.94 to 1.81) | 0.107 |
| Baseline DAS28-CRP | 1.22 | (0.88 to 1.71) | 0.237 |
| Baseline CRP (mg/L) | 1.10 | (1.02 to 1.18) | 0.018 |
| Bivariate models | |||
| Baseline MBDA adjusted for DAS28-ESR | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for DAS28-CRP | 1.05 | (1.02 to 1.09) | <0.001 |
| Baseline MBDA adjusted for CRP | 1.06 | (1.02 to 1.10) | 0.002 |
| Baseline MBDA adjusted for ESR | 1.04 | (1.01 to 1.07) | 0.021 |
| Baseline MBDA adjusted for rheumatoid factor | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for CCP status | 1.05 | (1.03 to 1.08) | <0.001 |
| Baseline MBDA adjusted for total swollen joint count | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for total tender joint count | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for global assessment of disease activity | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for SHS | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for symptom duration | 1.05 | (1.02 to 1.08) | <0.001 |
| Baseline MBDA adjusted for sex | 1.05 | (1.02 to 1.08) | <0.001 |
| Multivariate model‡ | |||
| Baseline MBDA adjusted for sex, symptom duration, baseline erosions, current smoking status, HAQ score | 1.05 | (1.02 to 1.08) | <0.001 |
| High (>44) baseline MBDA score adjusted for sex, symptom duration, baseline erosions, current smoking status, HAQ score | 3.86 | (1.04 to 14.26) | 0.04 |
*The OR was estimated from a logistic regression model. The logistic model is estimating the probability of radiographic progression at 1 year. For the univariate model, the odds of radiographic progression increases by 5% for every 1-unit increase in the baseline MBDA score. When accounting for other disease activity measures individually (bivariate models), the odds of radiographic progression increase in a cumulative manner, approximately 4–6% for every 1-unit increase in the baseline MBDA score.
†p Value was calculated using Wald's χ2 test.
‡Multivariate model adjusted for significant univariate predictors of 1-year radiographic progression (n=207), as in Saevarsdottir et al.37
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28-CRP, disease activity score based on C-reactive protein; DAS28-ESR, disease activity score based on erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MBDA, multi-biomarker disease activity; SHS, Sharp–van der Heijde score.